Nabriva (NBRV) Aims To Resubmit Contepo NDA In Q4
Zacks Investment Research | Aug 19, 2019 05:55AM ET
Nabriva Therapeutics plc (NASDAQ:NBRV) announced that it plans to resubmit a new drug application (NDA) for Contepo (Fosfomycin) injection to the FDA early in the fourth quarter of 2019. A potentially first-in-class epoxide intravenous antibiotic Contepo is being developed for treating patients with complicated urinary tract infection (cUTI) including acute pyelonephritis.
The decision came following the receipt of the final Type A Meeting minutes from the regulatory body.
In April this year, Nabriva received a Complete Response Letter (CRL) from the FDA in connection with the NDA for Contepo regarding facility inspections and manufacturing deficiencies at one of its contract manufacturers. The company had filed the NDA for Contepo last October for treating the given patient population.
The FDA has neither requested any new clinical or non-clinical data nor raised any concerns about the safety and efficacy of Contepo post the meeting. The regulatory agency will review the resubmission within six months of the receipt date, which will now be designated as “Class 2.”
The company is looking forward to bring this important treatment option to patients as quickly as possible.
Shares of Nabvira have soared 56.2% so far this year against the industry’s decline of 2%.
We would like to remind investors that apart from Contepo, the company has another candidate in its portfolio called lefamulin, which is a potentially first-in-class, semi-synthetic pleuromutilin antibiotic available for oral as well as intravenous (IV) administration in humans to address community-acquired bacterial pneumonia (CABP).
Notably, last December, Nabvira submitted two new drug applications to the FDA for both the IV and oral formulations of lefamulin to treat CABP in the United States. A decision is expected shortly.
In June this year, the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA), seeking approval for both IV and oral formulations of lefamulin for the treatment of community-acquired pneumonia (CAP) in adult patients.
If approved, lefamulin will be available across all the 28 member states of the EU along with Norway, Liechtenstein and Iceland.
Zacks Rank & Other Stocks to Consider
Nabvira currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the healthcare sector include FibroGen, Inc (NASDAQ:FGEN) , Celcuity, Inc. (NASDAQ:CELC) and Eton Pharmaceuticals, Inc. (NASDAQ:ETON) , all sporting a Zacks Rank #1 (Strong Buy). You can see .
Get The News You Want
FibroGen’s loss per share estimates have been narrowed 57.5% for 2019 and 64.2% for 2020 over the past 60 days.
Celcuity’s loss per share estimates have been narrowed 13.6% for 2019 and 26% for 2020 over the past 60 days.
Eton Pharmaceuticals’ loss per share estimates have been narrowed 26.2% for 2019 and 51.5% for 2020 over the past 60 days.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.